 The FDA approved it in 1998, making it the first approved TNF inhibitor.Infliximab has shown significant success in treating both Crohn's disease and ulcerative colitis, but it is also approved for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.Adalimumab was approved by the FDA in 2002, becoming the first fully human monoclonal antibody to be approved.